Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. clinical trials
Acquired by Sino Biopharmaceutical Limited
The registry lists 6 studies whose lead sponsor is Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 22, 2025.
Where
- China
- 5
Registry sponsor names on this page
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.6 studies
Something wrong with this grouping? Tell us on the Sino Biopharmaceutical Limited page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Sino Biopharmaceutical Limited studies →
- FHND1002 for ALS Treatment: Phase 2Not yet recruitingNCT07138014Phase 2
Sponsor listed in the registry: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy AdultsEnrolling by invitationNCT06782958Phase 1
Sponsor listed in the registry: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal ConditionsEnrolling by invitationNCT06762743Phase 1
Sponsor listed in the registry: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- FHND9041 Versus Afatinib for Non-small Cell Lung CancerEnrolling by invitationNCT06759857Phase 3
Sponsor listed in the registry: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple MyelomaRecruitingNCT05271682Phase 1
Sponsor listed in the registry: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid TumorsStatus unknownNCT05818917Phase 1
Sponsor listed in the registry: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. — acquired company within the Sino Biopharmaceutical Limited group